Kim Jin Hyoung, Yoon Hyun-Ki, Sung Kyu-Bo, Ko Gi-Young, Gwon Dong Il, Shin Ji Hoon, Song Ho-Young
Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Cancer. 2008 Oct 1;113(7):1614-22. doi: 10.1002/cncr.23787.
The role of transcatheter arterial chemoembolization (TACE) or transcatheter arterial chemoinfusion (TACI) for unresectable intrahepatic cholangiocarcinoma (ICC) has recently been questioned. The aim of the study was to evaluate the clinical efficacy of TACE or TACI in patients with unresectable ICC and to identify prognostic factors associated with clinical success.
From 1997 to 2007, 49 patients with unresectable ICC were treated with TACE (n = 124) or transcatheter arterial chemoinfusion (TACI) (n = 96). Tumor response was evaluated based on computed tomography scans obtained 1 month to 3 months after TACE or TACI. Factors associated with clinical success were evaluated using multivariate logistic regression analysis. Factors associated with the survival period were evaluated using multivariate Cox regression analysis.
After treatment, 27 (55%) of the patients showed radiographic response. Multivariate analysis confirmed that tumor vascularity (odds ratio [OR], 31.2; P = .002) was the only independent factor associated with radiographic response. The median and mean survival periods in our study patients were 12 and 24 months. Multivariate Cox regression analyses showed that tumor size (OR, 2.64; P = .048), tumor vascularity (OR, 13.5; P < .001), and the Child-Pugh class (OR, 3.65; P = .014) were the independent factors associated with the length of the survival period.
Hepatic intra-arterial chemotherapy is well tolerated and may be effective to prolong survival of patients with unresectable ICC. Tumor vascularity is significantly associated with radiographic response. Large tumor size, tumor hypovascularity, and Child-Pugh class B were poor prognostic factors for determining the patient survival period.
经导管动脉化疗栓塞术(TACE)或经导管动脉化疗灌注术(TACI)在不可切除的肝内胆管癌(ICC)治疗中的作用最近受到质疑。本研究的目的是评估TACE或TACI治疗不可切除ICC患者的临床疗效,并确定与临床成功相关的预后因素。
1997年至2007年,49例不可切除ICC患者接受了TACE(n = 124)或经导管动脉化疗灌注术(TACI)(n = 96)治疗。根据TACE或TACI术后1个月至3个月获得的计算机断层扫描评估肿瘤反应。使用多因素逻辑回归分析评估与临床成功相关的因素。使用多因素Cox回归分析评估与生存期相关的因素。
治疗后,27例(55%)患者显示影像学反应。多因素分析证实,肿瘤血管(优势比[OR],31.2;P = 0.002)是与影像学反应相关的唯一独立因素。本研究患者的中位生存期和平均生存期分别为12个月和24个月。多因素Cox回归分析显示,肿瘤大小(OR,2.64;P = 0.048)、肿瘤血管(OR,13.5;P < 0.001)和Child-Pugh分级(OR,3.65;P = 0.014)是与生存期长短相关的独立因素。
肝动脉内化疗耐受性良好,可能有效延长不可切除ICC患者的生存期。肿瘤血管与影像学反应显著相关。肿瘤体积大、肿瘤血管少和Child-Pugh B级是决定患者生存期的不良预后因素。